GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.» Read More
Michael Mussallem, Edwards Lifesciences CEO, provides insight into the future of treating heart disease.
Michael Mussallem, Edwards Lifesciences CEO, discusses major strides the medical community has made in cardiovascular treatment.
Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
A major drug prescription benefits manager is pushing to change the skyrocketing pricing structure, reports CNBC's Meg Tirrell
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.
A federal appeals court has made a ruling on a top selling Alzheimer's drug that could make things difficult for drugmaker Actavis, reports CNBC's Meg Tirrell.
Mark Cuban said innovative tech in the pharmaceutical sector is going to be a game changer not only for health care, but for humanity.
Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.
Michael Weinstein, JPM, managing director of healthcare, joins CNBC's Meg Tirrell to discuss biosimilar, the threat to big pharmaceuticals, and how Johnson & Johnson will be affected.
Researchers at UC Irvine restored a key feature of young brains, the flexibility that allows for learning and creativity.
"You're going to have some wins and some that don't turn out," J&J chief Alex Gorsky tells CNBC. "But overall we're very confident."
Jeffrey Marrazzo, Spark Therapeutics CEO, and Dr. Jean Bennett, Spark Therapeutics advisor, discuss how advances in gene therapy are changing the way rare diseases are treated. And Gordon Gund, Gund Investment Corp. CEO, weighs in.
CNBC's Meg Tirrell breaks down all the biotech data coming out ahead of the ASCO Conference, and why Clovis Oncology's stock is climbing.
A new study suggests Viagra can fight malaria, which still infects millions and kills half a million people every year.
U.S. scientist Bill Nye, popularly known as "the Science Guy", has launched a Kickstarter to fund an satellite propelled by solar energy.
CNBC's Meg Tirrell takes a look at new cancer-fighting drugs and other therapies in the pipeline.
The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.
Pedialyte is going after a new market, and they don't have a bedtime...
Get the best of CNBC in your inbox